No abstract

IntroductionMelanoma-associated antigen 1 (MAGE1) expression in normal tissues is restricted to the testes, whilst being over-expressed in a number of human cancers. This feature of MAGE1 makes it a promising cancer biomarker. This study aimed to determine the expression of MAGE1 in esophageal squamous cell carcinoma (SCC) and its relationship with clinicopathological factors.MethodsThis is a cross-sectional study conducted on pretreatment endoscopic tissue specimens of 43 patients with non-metastatic esophageal SCC, admitted to Omid Hospital, Mashhad, Iran, between 2011 and 2013. Out of 127 esophageal SCC patients who had already enrolled in a trial of trimodality therapy, we chose 43 patients whose paraffin blocks of endoscopic samples were accessible, which we then stained for MAGE1 expression by immunohistochemistry. Correlation of MAGE1expression and clinicopathological data (age, sex, stage, grade, and outcome) was assessed using SPSS 16 by T test, chi-square, and Pearson tests (p <0.05 was considered significant).ResultsMAGE1 was expressed in 46.5% (20 out of 43) of esophageal SCC specimens. The MAGE1 nuclear staining increased significantly by age; its expression for <40, 41–49, 50–59, 60–69, and ≥70 years old was 0%, 0%, 8.3%, 26.3%, and 100%, respectively (p=0.02; Person’s R value = 0.3 and p=0.04). There was no significant correlation between MAGE1 expression and other clinicopathological parameters.ConclusionMAGE1 antigen has considerable expression in the esophageal SCC among the Iranian population; it can be potentially applied as a cancer biomarker as well as a target for immunotherapy in patients with esophageal SCC.

Management of the central nervous system malignancies are among the evolving areas of research and clinical practice requiring a well-coordinated interdisciplinary approach. The neuro-oncology scientific club (NOSC) has tried to cross the links between various disciplines' experts involved in brain tumor care in Iran since 2011. The NOSC's structured collaborative brain tumor registry (BTCR) and the support received from its steering committee and provincial boards have been the key elements for its success and growth so far. This scientific community not only has helped to optimize brain tumor care but provided interdisciplinary research opportunities to its members across Iran. Mashhad's NOSC has been the pioneer in the above. During the 3 rd Mashhad's NOSC meeting held in November 21 st 2013, the interim results from some important local neuro-oncology studies were presented. Some potential opportunities to improve the coordinated interdisciplinary brain tumor care within the province were discussed by neurosurgery, neuroradiology and radiation oncology faculty at this provincial NOSC meeting. Clinical outcome, survival data and prognostic factors in adult and pediatric gliomas over the past several years in Mashhad, the association between methyl guanine methyl transferase (MGMT) methylation status (determined by MSQP or methylation specific quantitative polymerase chain reaction) where among the main studies outlined during this event. We realize that optimized brain tumor management and productive research in neuro-oncology can only be achieved through an integrated approach and strong team work. This is what the NOSC pursues.

No abstract

No abstract